What the studies show
Reported in 9–21% of treated participants vs 0.7% on placebo in TRIUMPH-4 — an effect not prominent with older GLP-1 drugs.
Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.
- 1Eli Lilly. Retatrutide delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful phase 3 trial (TRIUMPH-4).Press release, 11 Dec 2025445 adults, 68 weeks. Topline; not peer-reviewed.
In context
Retatrutide is an investigational once-weekly peptide that activates three receptors at once: GIP, GLP-1 and glucagon. Phase 3 topline results announced in December 2025 and May 2026 report average weight loss of about 26–29% at 68–80 weeks — the largest yet for a single drug — with high rates of nausea and more people stopping for side effects than on placebo. The full data are not yet peer-reviewed. It is not approved anywhere, and no legitimate supply exists outside clinical trials.
Retatrutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Retatrutide proven to cause dysesthesia?
What studies are behind the grade?
Is Retatrutide approved for this?
Other outcomes for Retatrutide
- BBody weight1 phase 2 RCT published; 2 phase 3 RCTs topline
- BKnee osteoarthritis pain1 phase 3 RCT topline
- BGI side effectsadversePhase 2 + phase 3 topline
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →